EQS-Adhoc

First Trading Day of New Kuros Share after Reverse Split

EQS Group-Ad-hoc: Kuros Biosciences AG / Key word(s): Miscellaneous
First Trading Day of New Kuros Share after Reverse Split

23.06.2016 / 18:31
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

First Trading Day of New Kuros Share after Reverse Split

Schlieren (Zurich), Switzerland, June 23, 2016 - Kuros Biosciences Ltd
("Kuros") today announced the first trading day of the new shares after a
reverse split at the ratio of 100 to 1 approved by the recent Annual
Shareholders' Meeting.

"The reverse split is expected to simplify the trading and increase the
shares' attractiveness for investors", explained Harry Welten, Chief
Financial Officer.

Shareholders approved the reverse stock split at the Annual Shareholders'
Meeting on June 16, 2016. 100 existing registered shares with a nominal
value of CHF 0.01 each were exchanged into 1 new (merged) registered share
with a nominal value of CHF 1.00. To allow the allocation of a rounded
number of shares, current shareholders and founders Dr. Jeffrey Hubbell and
Didier Cowling provided the other shareholders for no consideration with
the number of shares required. As a result, each existing shareholder
received at least one new (merged) share and in any event, a rounded number
of shares.

For further information, please contact:
Kuros Biosciences Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: [phone]
[e-mail]

About Kuros Biosciences Ltd

Kuros Biosciences Ltd is focused on the development of innovative products
for tissue repair and regeneration and is located in Schlieren (Zurich),
Switzerland. The Company is listed according to the International Reporting
Standard on the SIX Swiss Exchange Ltd under the symbol KURN. Information
regarding Kuros is available at www.kuros.ch.

Forward Looking Statements
This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. You are urged to consider
statements that include the words "will" or "expect" or the negative of
those words or other similar words to be uncertain and forward-looking.
Factors that may cause actual results to differ materially from any future
results expressed or implied by any forward-looking statements include
scientific, business, economic and financial factors, Against the
background of these uncertainties, readers should not rely on forward-
looking statements. The Company assumes no responsibility for updating
forward-looking statements or adapting them to future events or
developments.

End of ad hoc announcement
Additional features:


Document: http://n.eqs.com/c/fncls.ssp?u=HBXYVQPTKN
Document title: Kuros_Reverse_Split_23062016

---------------------------------------------------------------------------

23.06.2016 News transmitted by Tensid EQS AG. www.eqs.com

The issuer is responsible for the contents of the release.

---------------------------------------------------------------------------


Language: English
Company: Kuros Biosciences AG
Wagistrasse 25
8952 Schlieren
Switzerland
Phone: [phone]
Fax: [phone]
E-mail: [e-mail]
Internet: www.kuros.ch
ISIN: CH0011025217
Valor: -
Listed: Foreign Exchange(s) SIX


End of News EQS Group News Service
---------------------------------------------------------------------------

473985 23.06.2016